NBSE — NeuBase Therapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for NeuBase Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 3 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-Q |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 25.5 | 17.1 | 26.6 | 33.3 | 4.6 |
| Operating Profit | -25.5 | -17.1 | -26.6 | -33.3 | -4.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -26.1 | -17.4 | -25.4 | -33.8 | -4.37 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -26.1 | -17.4 | -25.4 | -33.8 | -4.37 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -26.1 | -17.4 | -25.4 | -33.8 | -4.37 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -26.1 | -17.4 | -25.4 | -33.8 | -4.37 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -63.2 | -17.7 | -18.6 | -20.8 | -2.25 |
| Dividends per Share |